Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Position Raised by Swiss National Bank

Swiss National Bank lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 168,783 shares of the biotechnology company’s stock after acquiring an additional 2,700 shares during the quarter. Swiss National Bank owned approximately 0.18% of Sarepta Therapeutics worth $20,522,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. raised its holdings in shares of Sarepta Therapeutics by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock valued at $75,842,000 after purchasing an additional 12,000 shares in the last quarter. Geode Capital Management LLC grew its stake in Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after buying an additional 44,306 shares during the last quarter. Summit Partners Public Asset Management LLC grew its stake in Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after buying an additional 116,800 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in Sarepta Therapeutics in the 4th quarter valued at $3,829,000. Finally, Larson Financial Group LLC grew its stake in Sarepta Therapeutics by 1,649.8% in the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock valued at $1,093,000 after buying an additional 8,249 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on SRPT. Royal Bank of Canada lowered their target price on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. HC Wainwright restated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Scotiabank started coverage on shares of Sarepta Therapeutics in a research report on Friday, March 7th. They issued a “sector perform” rating and a $105.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday. Finally, StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $170.23.

Sarepta Therapeutics Stock Down 27.4 %

Shares of NASDAQ SRPT opened at $73.54 on Wednesday. The firm’s 50-day simple moving average is $110.18 and its 200 day simple moving average is $119.13. The company has a market cap of $7.14 billion, a price-to-earnings ratio of 58.83 and a beta of 0.79. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12-month low of $73.06 and a 12-month high of $173.25.

Insider Buying and Selling

In related news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.